He said that “clinical trials are currently underway where two groups of volunteers: one receives two vaccinations with an interval of 21 days, and a separate group of volunteers who receive three doses of vaccinations - when the first two vaccines are injected with an interval of 21 days, and the third vaccine 60 days after the second ”.
"Such clinical studies are at the stage of implementation, taking into account the duration of the interval between the second and third immunizations - 60 days, we expect to receive the first results by the fall," RIA Novosti Maksyutova quotes.
In April, the head of the Russian Ministry of Health, Mikhail Murashko, announced that EpiVacCorona began to enter the country's medical institutions.